Month: September 2019

TEAM Yuqiao (Jerry) Shen, Ph.D. Chief Executive Officer, Co-founder BOARD OF DIRECTORS Dr. Shen brings more than 20 years of pharmaceutical drug development experience spanning from early discovery to phase 3 clinical trials.  Before founding AceLink in 2018, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development.  He joined… Continue reading YUQIAO (JERRY) SHEN

TEAM Michael Babcock, Ph.D. VICE PRESIDENT, RESEARCH & EARLY DEVELOPMENT Dr. Babcock has 18 years of pharmaceutical industry experience leading drug development and exploratory research projects. At Elan Pharmaceuticals, Dr. Babcock applied genetic, histopathology, and cell biology approaches to better understand the connections between lysosomal dysfunction and Parkinson’s disease. Dr. Babcock then joined BioMarin where… Continue reading MICHAEL BABCOCK

TEAM Li Li, Ph.D. Vice President, Operation, Co-founder BOARD OF DIRECTORS Dr. Li has more than 20 years of industry experience in business development and project management in the biotech field. Prior to co-founding AceLink Therapeutics, Dr. Li was a Senior Director of Business Development at Crown Bioscience, a leading translational technology platform company. She… Continue reading LI LI

TEAM LEONARD POST, PH.D. BOARD OF DIRECTORS | SCIENTIFIC ADVISORY BOARD Dr. Post is Vivace’s Chief Scientific Officer and a member of the board of directors, bringing more than three decades of pharmaceutical experience spanning companies of all sizes. Before joining Vivace in 2016, he served as chief scientific officer of BioMarin, a publicly held biopharmaceutical… Continue reading LEONARD POST

TEAM Jianhong Zheng, Ph.D. Vice President, China operation, Co-founder Dr. Zheng brings to AceLink an extensive experience in drug research and development. She obtained a Bachelor of Science degree in Microbiology from Fudan University, and earned PhD in Molecular Microbiology and Immunology from University of Missouri-Columbia. With a research fellowship from NIH, she completed postdoctoral… Continue reading Jianhong Zheng

TEAM Adam Shaywitz, M.D., PH.D. SCIENTIFIC ADVISORY BOARD Adam Shaywitz, M.D., Ph.D. is Chief Medical Officer (CMO)-in-Residence at BridgeBio Pharma where he currently serves as CMO for three subsidiary companies – CoA Therapeutics, Aspa Therapeutics and Adrenas Therapeutics. Prior to joining BridgeBio he worked for five years at BioMarin Pharmaceutical where he served as an… Continue reading ADAM SHAYWITZ

TEAM CHANGLING MEI, M.D. Advisors and Consultants Dr. Mei is a renowned nephrologist and scientist. He is Professor of Internal Medicine at Shanghai Changzheng Hospital, an affiliated teaching hospital of the Second Military Medical University. He served as Chairman at Department of Nephrology in Changzheng Hospital and was the Founding Director of Kidney Institute. He… Continue reading CHANGLING MEI

TEAM Henry Hulter, M.D. SCIENTIFIC ADVISORY BOARD Henry Hulter, MD is Emeritus Professor of Medicine (Nephrology) at UCSF with an academic research career centered in renal acid-base transport, electrolyte transport and divalent ion and bone metabolism in animal models and in clinical studies.  He has served as a consultant in drug discovery and development to… Continue reading Henry Hulter

TEAM THAMINDA RAMANAYAKE, M.B.A., M.S. Advisors and Consultants Mr. Ramanayake is a top business veteran with extensive experience in corporate and business development, strategy, transactions, and management of multi-disciplinary dynamic teams in the biotech and pharmaceutical sectors. Mr. Ramanayake has a strong track record in company creation, in/out-licensing, M&A, joint ventures, and cross-border transactions. He… Continue reading THAMINDA RAMANAYAKE

TEAM James J. Zhu, J.D, MBA, PH.D. Advisors and Consultants Dr. Zhu is a Partner at JunHe LLP (a Chinese firm with over 700 attorneys in China). He is the head of intellectual property (IP) practice and the managing partner of its Silicon Valley office.  Prior to JunHe, he was a partner at the Los… Continue reading JAMES J. ZHU